RedHill Biopharma Ltd (ADR) - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
RDHL Nasdaq 2836 https://www.redhillbio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for RedHill Biopharma Ltd (ADR)

RedHill Biopharma Announces Plan to Implement ADS Ratio Change - Mar 16th, 2023 10:15 pm
RedHill Biopharma Announces Definitive Agreement for Up To $6 Million Private Placement with a Single Investor - Mar 9th, 2023 12:05 am
RedHill Biopharma Ltd Announces RDHL Opaganib Selected by NIH RNCP For Development - Feb 28th, 2023 1:01 pm
RedHill's Opaganib Selected by the NIH Radiation and Nuclear Countermeasures Program - Feb 28th, 2023 12:00 pm
RedHill Biopharma Ltd Announces RedHill's RHB-102 Positive MHRA Meeting & MAA Plan - Feb 16th, 2023 1:01 pm
RedHill Announces Positive MHRA Meeting and Planned UK Marketing Authorisation Application of RHB-102 (BEKINDA®) for Oncology Support - Feb 16th, 2023 1:00 pm
RedHill Biopharma Announces Positive FDA Meeting Regarding Opaganib for Acute Nuclear Radiation Syndrome - Feb 15th, 2023 12:00 pm
Raleigh pharma sheds debt in exchange for top-selling drug. Now what? - Feb 10th, 2023 8:10 pm
RedHill Biopharma and HealthCare Royalty Agree to Extinguish All RedHill's Debt Obligations in Exchange for Movantik® - Feb 6th, 2023 12:00 pm
RedHill Receives USPTO Notice of Allowance for a Patent Covering Phase 3-stage RHB-204 for the Treatment of NTM Disease - Jan 26th, 2023 12:00 pm
RedHill Biopharma Shares Jump After Data Publication From COVID-19 Study - Jan 3rd, 2023 4:07 pm
RedHill Announces Publication of Positive Phase 2 Study Results with Once-Daily Oral RHB-107 in Non-Hospitalized COVID-19 - Jan 3rd, 2023 12:00 pm
2022 Year in Review: Layoffs hit Triangle biotech, pharma companies - Dec 27th, 2022 7:53 pm
Aegis Capital Corp. Acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for RedHill Biopharma Ltd. (NASDAQ:RDHL) - Dec 7th, 2022 2:45 pm
RedHill Biopharma Closes $8.0 Million Underwritten Public Offering - Dec 6th, 2022 6:36 pm
RedHill Biopharma Prices $8.0 Million Underwritten Public Offering - Dec 2nd, 2022 2:00 pm
RedHill Biopharma Announces Proposed Public Offering - Dec 1st, 2022 9:01 pm
RedHill Biopharma Announces Q3/22 Results and Operational Highlights - Nov 29th, 2022 1:00 pm
The RedHill Biopharma Ltd. (NASDAQ:RDHL) Analyst Just Cut Their Revenue Forecast By 23% - Nov 24th, 2022 10:19 am
RedHill Biopharma Announces Positive New Data with Opaganib for Nuclear Radiation Injury - Nov 17th, 2022 1:30 pm